English

BioStock: Top oncologist underscores BioInvent’s potential for “Immunotherapy 2.0”

Report this content

BioInvent recently announced promising clinical data for its lead cancer immunotherapy candidates, BI-1808 and BI-1206. The company hosted a Key Opinion Leader webinar to explain the results in detail, featuring insights from internationally recognized oncologist Dr Alexander Eggermont. According to Dr Eggermont, BioInvent’s candidates hold great promise for the future of immuno-oncology.

Read the article at biostock.se:

Top oncologist underscores BioInvent’s potential for “Immunotherapy 2.0” - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Subscribe

Documents & Links

Quick facts

BioStock: Top oncologist underscores BioInvent’s potential for “Immunotherapy 2.0”
Tweet this